2023 µ¿°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼ó : 2023-02-11±³À°ÀÏÀÚ : 2023-02-11
±³À°Àå¼Ò : Áß¾Ó´ëÇб³º´¿ø Áß¾Ó°ü 4Ãþ ¼ÛºÀȦ
±³À°ÁÖÁ¦ :
2023 µ¿°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼óÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÐÀÚÆó¾Ï¿¬±¸È¸
´ã´çÀÚ : ±è¹Ì¼±
¿¬¶ôó : 02-575-3825
À̸ÞÀÏ :
katrd@hanmail.net ±³À°Á¾·ù : ³»°úÀÇÇб³À°, ±âŸ
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã ±³À°½Ã°£ : 3 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï : 10000¿ø ÇöÀåµî·Ï : 20000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 13:10~13:35 How to Survive as an Early-career Researcher Who Studies Lung Cancer ±è¿¬¿í(¼¿ïÀÇ´ë ³»°ú)
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 13:35~14:00 Research Experience as a Young Respiratory Physician ¾ÈÁØÈ«(¿µ³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 14:00~14:25 Biomarker Research for Early Diagnosis and Prediction of Treatment Response in Lung Cancer ÀÓÁØÇõ(ÀÎÇÏÀÇ´ë ³»°ú)
ÈÞ½Ä 02-11 ¼ÛºÀȦ 14:30~14:40 Coffee Break ()
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 14:40~15:05 Neoadjuvant Therapy Strategies : need to be ¡°Personalized¡± ±èÀº¿µ(¿¬¼¼ÀÇ´ë ³»°ú)
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 15:05~15:30 Adjuvant Therapy for NSCLC : Closer to Cure or Just Delaying Progression? ±è¹ÌÇö(ºÎ»êÀÇ´ë ³»°ú)
ÈÞ½Ä 02-11 ¼ÛºÀȦ 15:30~15:45 Coffee Break ()
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 15:45~16:10 Apto_RADS : Multicenter Clinical Evaluation Study of Clinical Effectivity of AptoDetect-Lung for Auxiliary Diagnostics of NSCLC À̽ÂÇö(°æÈñÀÇ´ë ³»°ú)
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 16:10~16:35 BUDDY Trial : Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in NSCLC ¿ÀÀÎÀç(Àü³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 16:35~17:00 Lazertinib study based on EV-based BALF liquid biopsy À̰迵(°Ç±¹ÀÇ´ë ³»°ú)
±³À°½Ã°£ 02-11 ¼ÛºÀȦ 17:00~17:25 PLATINUM Trial : A Phase II, Multicenter study of Lazertinib as Consolidation Therapy in Patients with Unresectable EGFR-mutant NSCLC following CCRT ÀÌÁ¤Àº(Ãæ³²ÀÇ´ë ³»°ú)